Joseph Merrick, the Victorian-era figure known as the “Elephant Man,” almost certainly suffered from Proteus syndrome, an extraordinarily rare genetic disorder that causes asymmetric, progressive overgrowth of bone, skin, and other tissues. For most of the twentieth century, his condition was attributed to a different disease entirely, and untangling that misdiagnosis has taken more than a hundred years of medical detective work that is still ongoing.
A Century of the Wrong Diagnosis
Merrick was first presented to the Pathological Society of London in 1884 by the surgeon Sir Frederick Treves, who would later arrange for him to live at the London Hospital.1PubMed Central. The Proteus syndrome: the Elephant Man diagnosed At the time, no formal diagnosis was attached to his appearance. In 1909, a dermatologist named Parkes suggested that Merrick had neurofibromatosis, a condition that causes tumors to grow along nerves. That diagnosis stuck. It was repeated in medical textbooks, in popular culture, and most prominently in the 1980 David Lynch film, which cemented “Elephant Man disease” as a casual synonym for neurofibromatosis type 1 in the public imagination.
The problem was that the diagnosis never quite fit. Neurofibromatosis type 1 does cause skin growths and bone abnormalities, but it typically produces many small, soft tumors called neurofibromas spread relatively symmetrically across the body, along with characteristic flat brown spots on the skin called café-au-lait macules. Merrick’s condition was strikingly different. His overgrowth was massive, irregular, and heavily concentrated on one side of his body. His skull was enormously enlarged, his right arm and both legs were thickened with bony overgrowth, and his skin hung in thick, folded masses. These features did not match the textbook picture of neurofibromatosis.
The 1986 Reclassification
In 1986, two Canadian geneticists, Michael Cohen and Judith Hall, re-examined descriptions and images of Merrick and concluded that he had Proteus syndrome rather than neurofibromatosis type 1.2PubMed Central. Neurofibromatosis type 1 and the “elephant man’s” disease: the confusion persists: an ethnographic study Proteus syndrome had only recently been described as a distinct condition in the early 1980s, so earlier physicians simply did not have it as a diagnostic option. Cohen and Hall laid out the features of Merrick’s body that aligned with Proteus syndrome: macrocephaly (an abnormally large skull), hyperostosis (excessive bone growth) of the skull, hypertrophy (enlargement) of the long bones, and dramatically thickened skin and subcutaneous tissues, particularly on the hands and feet, including plantar hyperplasia and fatty growths called lipomas.1PubMed Central. The Proteus syndrome: the Elephant Man diagnosed
This reclassification was widely accepted in the medical genetics community. Yet the older label has proved remarkably persistent. A study examining how people understand the link between Merrick and neurofibromatosis found that the confusion endures decades after the correction, in part because cultural representations of Merrick continue to reinforce the outdated diagnosis.2PubMed Central. Neurofibromatosis type 1 and the “elephant man’s” disease: the confusion persists: an ethnographic study Advocacy organizations for neurofibromatosis have spent years trying to distance themselves from the association, since the frightening images of Merrick do not represent what most people with neurofibromatosis look like.
What Proteus Syndrome Actually Does to the Body
Proteus syndrome is defined by disproportionate, asymmetric overgrowth. Unlike conditions that affect the body in a relatively uniform way, Proteus syndrome tends to enlarge some parts dramatically while leaving neighboring structures relatively untouched. The overgrowth is progressive, meaning it tends to worsen over time, and it can affect virtually any tissue type: bone, skin, fat, blood vessels, and connective tissue. No two patients look exactly alike, which is part of why the condition went unrecognized for so long.
In Merrick’s case, the right side of his body bore much of the burden. His skull had grown to a circumference reportedly around 36 inches. A bony mass protruded from his forehead. His right arm was useless, massively thickened from shoulder to fingertip. His skin, especially on the back and lower limbs, had a rough, bark-like texture with deep folds and hanging masses. His spine was severely curved, and the bony overgrowth of his legs made walking painful and difficult. His left arm, by contrast, remained relatively normal, and his genitalia were unaffected. This patchwork quality of the disease is one of its hallmarks.
The condition is exceptionally rare. Fewer than a few hundred cases have been confirmed worldwide since it was first described as a named syndrome. Because the overgrowth is progressive and can affect internal organs and blood vessels, people with severe forms face serious medical complications including blood clots, skeletal deformities that compress the airway or spinal cord, and a heightened susceptibility to certain types of tumors.
The Genetic Cause and Why It Is Not Inherited
The molecular cause of Proteus syndrome was identified in 2011, when researchers discovered that the condition results from a somatic activating mutation in a gene called AKT1. This mutation switches on a growth-signaling pathway that causes affected cells to proliferate excessively.3PubMed Central. A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome The word “somatic” is key here: the mutation arises spontaneously in a single cell sometime after the fertilized egg begins dividing. It is not present in the sperm or egg that created the embryo, so it is not inherited from either parent.
Because only some cells carry the mutation while the rest of the body is genetically normal, the condition is described as mosaic. This explains the characteristic patchwork pattern of overgrowth. The tissues that descend from the original mutated cell carry the faulty gene and tend to overgrow; neighboring tissues derived from non-mutant cells develop normally. The earlier in embryonic development the mutation occurs, the more of the body ends up carrying it, which is why some patients are severely affected and others have relatively limited disease.4PubMed Central. Disorders Caused by Genetic Mosaicism
This mosaic origin has an important practical consequence for families. Because the mutation is not present in the parents’ reproductive cells, there is essentially no elevated risk that another child will be born with the same condition. For parents who have a child diagnosed with Proteus syndrome, this finding offers significant reassurance.4PubMed Central. Disorders Caused by Genetic Mosaicism It also explains why the condition does not run in families the way, say, neurofibromatosis type 1 does, which is passed from parent to child through a germline mutation that is present in every cell.
Novel variants of AKT1 mutations continue to be found. A case report documented a previously unknown type of somatic AKT1 duplication in a patient with Proteus syndrome, illustrating that the same gene can be disrupted in more than one way while still producing the characteristic overgrowth phenotype.5PubMed Central. Proteus syndrome caused by novel somatic AKT1 duplication
Why Genetic Confirmation From Merrick Himself Remains Elusive
Merrick died in 1890 at the age of 27, likely from suffocation after his heavy head fell backward and compressed his airway while he tried to sleep lying down. His skeleton has been preserved at the Royal London Hospital ever since, and it remains the most direct evidence available for confirming or refining his diagnosis. Researchers have attempted to extract DNA from his remains, but the process is difficult. More than 130 years of preservation, handling, and environmental exposure have degraded whatever genetic material might remain in the bones.
A clinical review concluded that applying modern diagnostic criteria to the historical descriptions of Merrick’s body makes Proteus syndrome the overwhelming likely diagnosis, but noted that his genotype remains unknown and that intact DNA from the skeleton would be needed for definitive genetic confirmation.6PubMed. Clinical and historical aspects of the Elephant Man: exploring the facts and the myths If sequencing were possible, researchers could look for the AKT1 mutation that has been found in living Proteus syndrome patients. That would settle the question beyond any remaining clinical doubt.
More recent efforts have involved imaging Merrick’s bones and the plaster casts of his soft tissues using photography, X-rays, and CT scans, alongside taking fresh bone samples from the skull for genetic analysis.7Radiological Society of North America. The Elephant Man Revisited: The Latest Results The results of these newer genetic analyses have not yet produced a published confirmation of the AKT1 mutation, but the imaging work continues to refine the understanding of just how extensive Merrick’s skeletal overgrowth was.
Could Merrick Have Had Both Conditions
Some researchers have raised the possibility that Merrick may have had neurofibromatosis in addition to Proteus syndrome, since the two conditions are not mutually exclusive and some historical descriptions of his skin lesions could be interpreted as neurofibromas. A few features mentioned in contemporary clinical accounts, such as certain pendulous skin growths, are more typical of neurofibromatosis than of Proteus syndrome alone.
This “dual diagnosis” hypothesis remains a minority view. The 1986 reclassification team and most subsequent reviewers have found that Proteus syndrome alone accounts for the full range of Merrick’s features when viewed through the lens of modern diagnostic criteria. The difficulty is that in the 1880s, clinical descriptions were less standardized, and no tissue biopsies were preserved in a way that allows modern histological analysis. Without genetic evidence from Merrick’s own tissues, the question of whether he had overlapping conditions cannot be definitively closed. But most specialists in overgrowth syndromes consider Proteus syndrome the single best explanation for everything observed in his body.
Proteus Syndrome Versus Similar Overgrowth Disorders
Part of the reason the Elephant Man’s diagnosis took so long to sort out is that Proteus syndrome sits in a cluster of related overgrowth conditions that share features and can look superficially similar. Several of these conditions involve the same growth-signaling pathway that AKT1 belongs to. The broader family of PIK3CA-related overgrowth spectrum, or PROS, includes conditions that also cause tissue overgrowth due to mutations in nearby genes on the same signaling cascade. These include CLOVES syndrome (characterized by lipomatous overgrowth, vascular malformations, and skeletal anomalies) and other mosaic overgrowth conditions.
The clinical overlap between these disorders means that diagnosis often requires genetic testing rather than relying on appearance alone. Before the molecular era, conditions that are now known to be genetically distinct were frequently lumped together under broad labels or misdiagnosed as one another. This was exactly the situation with Merrick: in the absence of genetic tools, the best anyone could do was pattern-match his features to whatever condition seemed closest, and neurofibromatosis was the most widely known option at the time.
Treatments That Did Not Exist in Merrick’s Lifetime
For most of the history of Proteus syndrome, treatment was limited to surgery to remove or reduce overgrown tissue, bracing or orthopedic interventions for skeletal deformities, and management of complications as they arose. There was no way to address the underlying cause. That has begun to change.
Because researchers now know that Proteus syndrome is driven by overactivation of the AKT signaling pathway, they have been able to repurpose drugs originally developed for cancer, where the same pathway is frequently overactive. Miransertib (originally known as ARQ 092) is a selective inhibitor of AKT that was initially designed for oncology use. A pilot study found that a dose about one-seventh of the typical cancer dose was enough to reduce AKT activity by half in affected tissues from five out of six patients. The drug was well tolerated, and researchers observed a decrease in a type of skin overgrowth and a reduction in pain in children receiving treatment.8PubMed Central. Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
A subsequent clinical report described one year of miransertib treatment in a patient with Proteus syndrome and concluded that the therapy was beneficial.9PubMed Central. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092) Larger trials are underway. The multicenter, open-label MOSAIC study is evaluating miransertib in patients with both Proteus syndrome and the related PIK3CA-related overgrowth spectrum to assess longer-term safety and efficacy.10PubMed Central. Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome
These are still early-stage efforts, and miransertib is not yet approved as a standard treatment for Proteus syndrome. But the trajectory is meaningful. For a condition that had no targeted therapy of any kind until very recently, even preliminary evidence of a drug that can slow overgrowth or reduce symptoms represents a genuine shift. Merrick, who died at 27 with no real medical options beyond shelter and sympathy at the London Hospital, would have been a different patient in a different century.
Why the Old Label Persists in Pop Culture
Despite the reclassification happening nearly four decades ago, “Elephant Man disease” remains casually equated with neurofibromatosis in popular media and everyday conversation. A study examining this persistence found that the association is deeply embedded in cultural narratives, reinforced by the 1980 film and by decades of medical textbooks that had already cemented the link before anyone knew Proteus syndrome existed.2PubMed Central. Neurofibromatosis type 1 and the “elephant man’s” disease: the confusion persists: an ethnographic study
This matters beyond trivia. People living with neurofibromatosis type 1 report that the association with Merrick’s extreme disfigurement creates stigma and fear that does not reflect their actual experience. Most individuals with neurofibromatosis have relatively mild symptoms: skin-colored bumps, freckling in the armpits or groin, and sometimes learning differences. The dramatic overgrowth seen in Merrick simply is not part of that condition. Conflating the two gives people a distorted picture of what a neurofibromatosis diagnosis means, and NF advocacy groups have worked to correct the record. The irony is that a diagnostic mistake from 1909, made by a single dermatologist working without the genetic tools to get it right, has shaped public perception of an unrelated disease for over a century.
Living With Proteus Syndrome Today
Because Proteus syndrome results from a random mutation during early embryonic development and is not inherited, there is no way to predict or screen for it before birth. It typically is not apparent at birth either. The overgrowth usually begins in infancy or early childhood and progresses over time, which means many families go through a period of worsening symptoms and multiple specialists before a diagnosis is reached. Genetic testing for the AKT1 mutation can now confirm the diagnosis, though the mosaic nature of the condition means the mutation might only be detectable in affected tissue, not in a standard blood sample.
Management remains multidisciplinary. Orthopedic surgeons address skeletal overgrowth and spinal deformities. Dermatologists manage the skin manifestations. Vascular specialists monitor for blood clots, which are a significant risk because abnormal blood vessel development is part of the condition. Pain management is often a major concern, particularly as bony overgrowth presses on nerves and joints. And psychosocial support matters, since visible disfigurement in a rare condition carries its own burden of isolation and stigma.
The identification of AKT1 as the causative gene has opened avenues beyond miransertib. Researchers are exploring whether other inhibitors of the PI3K-AKT pathway, some already in use for certain cancers, could be adapted for overgrowth syndromes. Gene-editing technologies are far too early in development for clinical use in mosaic conditions, but the fact that only a subset of cells carries the mutation makes it at least theoretically conceivable that targeted approaches could one day reduce the mutant cell population without affecting normal tissue. None of this is imminent, but the trajectory of the science has shifted from purely descriptive to mechanistically driven in a remarkably short span of time.